SMT201700219T1 - Hpn-100 per l’uso nel trattamento di disturbi da ritenzione di azoto - Google Patents
Hpn-100 per l’uso nel trattamento di disturbi da ritenzione di azotoInfo
- Publication number
- SMT201700219T1 SMT201700219T1 SM20170219T SMT201700219T SMT201700219T1 SM T201700219 T1 SMT201700219 T1 SM T201700219T1 SM 20170219 T SM20170219 T SM 20170219T SM T201700219 T SMT201700219 T SM T201700219T SM T201700219 T1 SMT201700219 T1 SM T201700219T1
- Authority
- SM
- San Marino
- Prior art keywords
- hpn
- treatment
- nitrogen retention
- retention disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636256P | 2012-04-20 | 2012-04-20 | |
| EP12874745.8A EP2846791B1 (en) | 2012-04-20 | 2012-09-11 | Hpn-100 for use in the treatment of nitrogen retention disorders |
| PCT/US2012/054673 WO2013158145A1 (en) | 2012-04-20 | 2012-09-11 | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201700219T1 true SMT201700219T1 (it) | 2017-05-08 |
Family
ID=49380684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20170219T SMT201700219T1 (it) | 2012-04-20 | 2012-09-11 | Hpn-100 per l’uso nel trattamento di disturbi da ritenzione di azoto |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9561197B2 (enExample) |
| EP (2) | EP3222275B1 (enExample) |
| JP (3) | JP6234436B2 (enExample) |
| KR (2) | KR102264579B1 (enExample) |
| CN (3) | CN104540507A (enExample) |
| AU (3) | AU2012377389A1 (enExample) |
| BR (1) | BR112014026138A2 (enExample) |
| CL (2) | CL2014002807A1 (enExample) |
| CY (1) | CY1118838T1 (enExample) |
| DK (1) | DK2846791T3 (enExample) |
| EC (1) | ECSP14024561A (enExample) |
| ES (2) | ES2807951T3 (enExample) |
| HR (1) | HRP20170651T1 (enExample) |
| HU (1) | HUE032726T2 (enExample) |
| IL (2) | IL235127A (enExample) |
| LT (1) | LT2846791T (enExample) |
| MX (1) | MX365302B (enExample) |
| PL (1) | PL2846791T3 (enExample) |
| PT (1) | PT2846791T (enExample) |
| RS (1) | RS55870B1 (enExample) |
| SG (2) | SG10201608749UA (enExample) |
| SI (1) | SI2846791T1 (enExample) |
| SM (1) | SMT201700219T1 (enExample) |
| WO (1) | WO2013158145A1 (enExample) |
| ZA (1) | ZA201407597B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107271696A (zh) | 2011-09-30 | 2017-10-20 | 海波龙治疗有限责任公司 | 氮清除药物的治疗性监测方法 |
| HUE032726T2 (en) | 2012-04-20 | 2017-10-30 | Horizon Therapeutics Llc | HPN-100 for use in the treatment of nitrogen retention disorders |
| SI2922576T1 (en) | 2012-11-21 | 2018-04-30 | Horizon Therapeutics, Llc | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| WO2015057747A1 (en) | 2013-10-14 | 2015-04-23 | Hyperion Therapeutics, Inc. | Methods of treating urea cycle disorders |
| EP3013372B1 (en) * | 2014-06-04 | 2019-07-10 | Immedica Pharma AB | Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| EP0858441B1 (en) | 1995-02-07 | 2001-05-09 | Brusilow Enterprises, LLC | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| PT2319581E (pt) | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| US20100016207A1 (en) | 2005-11-10 | 2010-01-21 | Wurtman Richard J | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| GB2451259B (en) * | 2007-07-25 | 2011-07-20 | Gp Acoustics | Loudspeaker |
| EP2237684A2 (en) | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| WO2009134460A1 (en) * | 2008-04-29 | 2009-11-05 | Hyperion Therapeutics | Methods of treatment using ammonia-scavenging drugs |
| PL2330892T3 (pl) * | 2008-08-29 | 2017-05-31 | Horizon Therapeutics, Llc | Sposoby leczenia z zastosowaniem leków wychwytujących amoniak |
| EP2338050A1 (en) | 2008-08-29 | 2011-06-29 | Ucyclyd Pharma, Inc. | Dosing and monitoring patients on nitrogen-scavenging drugs |
| US20110020312A1 (en) * | 2009-05-11 | 2011-01-27 | Niven Rajin Narain | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| WO2011011781A1 (en) | 2009-07-24 | 2011-01-27 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| WO2012028620A1 (en) | 2010-08-31 | 2012-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
| CN107271696A (zh) | 2011-09-30 | 2017-10-20 | 海波龙治疗有限责任公司 | 氮清除药物的治疗性监测方法 |
| HUE032726T2 (en) | 2012-04-20 | 2017-10-30 | Horizon Therapeutics Llc | HPN-100 for use in the treatment of nitrogen retention disorders |
| SI2922576T1 (en) | 2012-11-21 | 2018-04-30 | Horizon Therapeutics, Llc | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
-
2012
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active Active
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active Withdrawn
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 SM SM20170219T patent/SMT201700219T1/it unknown
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en not_active Ceased
-
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
-
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
-
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236000A0 (en) | Reverse thermal hydrogel preparations for use in the treatment of urothelial disorders | |
| IL238400A0 (en) | Triazolopyrazines as brd4 inhibitors for use in cancer therapy | |
| PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| IL225239A0 (en) | Compounds for the treatment of acne and related diseases | |
| IL263661A (en) | Combination therapy for the treatment of glioblastoma | |
| IL238027A0 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders | |
| IL237125A0 (en) | Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors | |
| IL235127A (en) | Hpn-100 for use in the treatment of nitrogen-related diseases | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| SMT201800251T1 (it) | Dispersione solida amorfa per l'uso nel trattamento del cancro del cervello | |
| EP2922536A4 (en) | USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE | |
| SG10201702375RA (en) | Telomerase inhibitors for use in therapy | |
| ZA201206898B (en) | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferatiive disorders | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| PT2872176T (pt) | Carboranilporpirinas para utilização no tratamento de cancro | |
| PL2861568T3 (pl) | Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| ZA201407164B (en) | Device for use in the treatment hyperbilirubinemia | |
| LT2863932T (lt) | Kompozicija, skirta naudoti limfedemos gydymui | |
| GB201223371D0 (en) | Novel mucinase for use in therapy or prophylaxis | |
| AU2012905072A0 (en) | The use of bucillamine in the treatment of gout |